Gilad Oren 4

What Happened
Gilad Oren, President, CEO and a director of Aprea Therapeutics (APRE), participated in a private placement that closed January 30, 2026. He acquired 28,100 shares of common stock at $0.89 per share for a cash outlay of $25,009 and also received common warrants to purchase up to 28,100 additional shares (warrants reported as a derivative acquisition).

Key Details

• Transaction date: January 30, 2026; Form 4 filed February 2, 2026.
• Common stock purchase: 28,100 shares @ $0.89 per share = $25,009.
• Derivative received: Common warrants to purchase up to 28,100 shares (no separate exercise price reported on the Form 4 line).
• Ownership after transaction: Not specified in the provided filing.
• Notable footnotes:
  • F1: Reporting person disclaims beneficial ownership of these securities.
  • F2: Shares and accompanying warrants were issued in a private placement under a securities purchase agreement dated Jan 28, 2026.
  • F3: Warrants are immediately exercisable but subject to ownership caps (cannot be exercised if doing so would push beneficial ownership above 4.99% or combined voting power above 9.99%).
  • F4: Warrants expire by the second anniversary of the earlier of registration effectiveness for the underlying shares or eligibility for sale under Rule 144 (with certain conditions).
• Filing timeliness: Report filed Feb 2, 2026 reporting the Jan 30, 2026 transaction; no late-filing flag indicated.

Context
This was a purchase in a private placement (a cash purchase of common stock plus warrants). Purchases by insiders are often of interest to retail investors as a straightforward sign of insider buying activity; the warrants add potential upside if exercised later but carry exercise and ownership-limit conditions. The filing includes a disclaimer of beneficial ownership (F1), and the warrants are subject to ownership caps and an expiration window described above.